4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

著者: Suresh S. Ramalingam, David Balli, T-E. Ciuleanu, Adam Płużański, Jin Sun Lee, Michael Schenker, R. Bernabe Caro, K.H. Lee, Roberta Bartolucci, Clarisse Audigier-Valette, Matthew D. Hellmann, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, Phuong Tran, Thomas Spires, William J. Geese, Sachin Agrawal - Annals of Oncology 2021 被引用: 25